These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 4019576)

  • 1. Initial Canadian experience with artificial blood (Fluosol-DA-20%) in severely anemic patients.
    Stefaniszyn HJ; Wynands JE; Salerno TA
    J Cardiovasc Surg (Torino); 1985; 26(4):337-42. PubMed ID: 4019576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemodynamic and oxygen transport effects of a perfluorochemical blood substitute, fluosol-DA (20%).
    Tremper KK; Lapin R; Levine E; Friedman A; Shoemaker WC
    Crit Care Med; 1980 Dec; 8(12):738-41. PubMed ID: 7449405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The preoperative treatment of severely anemic patients with a perfluorochemical oxygen-transport fluid, Fluosol-DA.
    Tremper KK; Friedman AE; Levine EM; Lapin R; Camarillo D
    N Engl J Med; 1982 Jul; 307(5):277-83. PubMed ID: 7045667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical experience with Fluosol-DA (20%) in the United States.
    Tremper KK; Levine EM; Waxman K
    Int Anesthesiol Clin; 1985; 23(1):185-97. PubMed ID: 3884514
    [No Abstract]   [Full Text] [Related]  

  • 5. Perfluorochemical emulsion oxygen transport fluids: a clinical review.
    Tremper KK; Anderson ST
    Annu Rev Med; 1985; 36():309-13. PubMed ID: 3888055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluosol DA-20 in the treatment of severe anemia: randomized, controlled study of 46 patients.
    Spence RK; McCoy S; Costabile J; Norcross ED; Pello MJ; Alexander JB; Wisdom C; Camishion RC
    Crit Care Med; 1990 Nov; 18(11):1227-30. PubMed ID: 1699704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of a 35% fluorocarbon emulsion.
    Gould SA; Sehgal LR; Rosen AL; Langdale LA; Sehgal HL; Krause L; Moss GS
    J Trauma; 1983 Aug; 23(8):720-4. PubMed ID: 6887290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Present status of clinical studies of Fluosol-DA (20%) in Japan.
    Mitsuno T; Ohyanagi H
    Int Anesthesiol Clin; 1985; 23(1):169-84. PubMed ID: 3980104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience with Fluosol-DA.
    Gould SA; Rosen AL; Sehgal LR; Sehgal HL; Moss GS
    Prog Clin Biol Res; 1983; 122():331-42. PubMed ID: 6878375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluosol-DA as a red-cell substitute in acute anemia.
    Gould SA; Rosen AL; Sehgal LR; Sehgal HL; Langdale LA; Krause LM; Rice CL; Chamberlin WH; Moss GS
    N Engl J Med; 1986 Jun; 314(26):1653-6. PubMed ID: 3713771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perfluorocarbons as blood substitutes: the early years. Experience with Fluosol DA-20% in the 1980s.
    Spence RK; Norcross ED; Costabile J; McCoy S; Cernaianu AC; Alexander JB; Pello MJ; Atabek U; Camishion RC
    Artif Cells Blood Substit Immobil Biotechnol; 1994; 22(4):955-63. PubMed ID: 7849967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a perfluorochemical whole blood substitute (Fluosol-DA, 20%)--an overview of clinical studies with 185 patients.
    Suyama T; Yokoyama K; Naito R
    Prog Clin Biol Res; 1981; 55():609-28. PubMed ID: 7027272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluosol DA-20% in treatment of severe anemia: ongoing studies in 52 patients.
    Spence RK; McCoy S; Costabile J; Norcross ED; Pello M; Alexander J; Atabek U; Wisdom C; Camishion R
    Biomater Artif Cells Immobilization Biotechnol; 1992; 20(2-4):1069. PubMed ID: 1391428
    [No Abstract]   [Full Text] [Related]  

  • 14. Changes of hemodynamics and O2 transport associated with the perfluorochemical blood substitute, Fluosol-DA.
    Nishimura N; Sugi T
    Crit Care Med; 1984 Jan; 12(1):36-8. PubMed ID: 6690204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular effects of various colloidal solutions during major abdominal surgery.
    Nishimura N; Hiranuma N; Sugi T
    Crit Care Med; 1983 Dec; 11(12):940-2. PubMed ID: 6196154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Fluosol-DA 20% in prehospital resuscitation.
    Elliott LA; Ledgerwood AM; Lucas CE; McCoy LE; McGonigal M; Sullivan MW
    Crit Care Med; 1989 Feb; 17(2):166-72. PubMed ID: 2914450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of blood and Fluosol-DA for cardiopulmonary bypass.
    Rousou JA; Engelman RM; Anisimowicz L; Dobbs WA
    J Cardiovasc Surg (Torino); 1985; 26(5):447-53. PubMed ID: 4030876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of plasma complement by perfluorocarbon artificial blood: probable mechanism of adverse pulmonary reactions in treated patients and rationale for corticosteroids prophylaxis.
    Vercellotti GM; Hammerschmidt DE; Craddock PR; Jacob HS
    Blood; 1982 Jun; 59(6):1299-1304. PubMed ID: 7082830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgical use of fluosol-DA in Jehovah's Witness patients.
    Ohyanagi H; Nakaya S; Okumura S; Saitoh Y
    Artif Organs; 1984 Feb; 8(1):10-8. PubMed ID: 6703920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the perfluorocarbon Fluosol-DA in coronary angioplasty.
    Kerins DM
    Am J Med Sci; 1994 Mar; 307(3):218-21. PubMed ID: 8160713
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.